Although this might reflect the challenges associated with IHC detection of phosphorylated epitopes in archival tissues, ERBB2 is not amplified or mutated in any of these prostate tissues, and thus the pathologic grading standards applied to HER2+ lung and breast tumors may not necessarily apply. Here, ERBB2 is linked to breast neoplasm.